不同放疗技术对全肺低剂量放疗治疗COVID-19肺炎的癌症风险估算
本研究基于32例COVID-19患者的CT图像,比较四种全肺低剂量放疗(处方剂量1 Gy)技术的剂量分布与辐射诱发癌症风险。IMRT和VMAT的心脏、乳腺、胃平均剂量及最大剂量均显著低于3D-CRT,适形指数相似而均匀性指数更优;肺癌发生风险各技术相似,但乳腺和胃等近肺器官的癌症发生与死亡风险在3D-CRT中更高。
要点
- IMRT和VMAT的心脏、乳腺、胃平均及最大剂量显著低于3D-CRT技术。
- 肺癌发生风险各技术相似(P>0.4),近肺器官癌症风险3D-CRT高于IMRT/VMAT。
- 所有技术癌症风险均低,IMRT和VMAT总体估算风险低于3D-CRT。
核心结论
- 所有放疗技术的癌症风险均低,但IMRT和VMAT的总体估算风险低于3D-CRT技术,可在年轻患者或对辐射诱发癌症更关注的患者中临床使用。
研究设计与样本
- 基于32例COVID-19患者的CT图像,对四种全肺低剂量放疗技术进行计划比较,处方剂量为全肺1 Gy。
主要发现
- IMRT和VMAT技术中心脏(平均和最大)、乳腺(平均和最大)、胃(平均)剂量及体内最大剂量均显著低于3D-CRT技术。
- 各技术计算的适形指数相似,但调强技术的均匀性指数更低(即更好)(P < 0.03),IMRT与VMAT计划间无显著差异。
- 所有照射技术的肺癌发生风险相似(P > 0.4)。
- 30岁男性超额实体瘤癌症发生风险:3D-CRT技术为1.94 ± 0.22%,IMRT/VMAT技术为1.68 ± 0.17%;30岁女性:3D-CRT技术为6.66 ± 0.81%,IMRT/VMAT技术为4.60 ± 0.43%。
- 30岁男性癌症死亡风险:3D-CRT技术为1.63 ± 0.19%,IMRT/VMAT技术为1.45 ± 0.15%;30岁女性:3D-CRT技术为3.63 ± 0.44%,IMRT/VMAT技术为2.94 ± 0.23%。
关键数值与推荐
- 全肺低剂量放疗处方剂量为1 Gy。
- IMRT和VMAT技术的心脏、乳腺、胃剂量及体内最大剂量显著低于3D-CRT技术。
- 调强技术均匀性指数更低(即更好)(P < 0.03)。
- 肺癌发生风险各技术相似(P > 0.4)。
临床怎么用
- 作者认为所有放疗技术的癌症风险均低,IMRT和VMAT的总体估算风险低于3D-CRT技术,可在年轻患者或对辐射诱发癌症更关注的患者中临床使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Low dose radiotherapy (LDRT) of whole lungs with photon beams is a novel method for treating COVID-19 pneumonia. This study aimed to estimate cancer risks induced by lung LDRT for different radiotherapy delivery techniques. METHOD: Four different radiotherapy techniques, including 3D-conformal with anterior and posterior fields (3D-CRT AP-PA), 3D-conformal with 8 coplanar fields (3D-CRT 8 fields), eight fields intensity-modulated radiotherapy (IMRT), and volumetric modulated arc therapy using 2 full arcs (VMAT) were planned on the CT images of 32 COVID-19 patients with the prescribed dose of 1 Gy to the lungs. Organ average and maximum doses, and PTV dose distribution indexes were compared between different techniques. The radiation-induced cancer incidence and cancer-specific mortality, and cardiac heart disease risks were estimated for the assessed techniques. RESULTS: In IMRT and VMAT techniques, heart (mean and max), breast (mean, and max), and stomach (mean) doses and also maximum dose in the body were significantly lower than the 3D-CRT techniques. The calculated conformity indexes were similar in all the techniques. However, the homogeneity indexes were lower (i.e., better) in intensity-modulated techniques (P < 0.03) with no significant differences between IMRT and VMAT plans. Lung cancer incident risks for all the delivery techniques were similar (P > 0.4). Cancer incidence and mortality risks for organs located closer to lungs like breast and stomach were higher in 3D-CRT techniques than IMRT or VMAT techniques (excess solid tumor cancer incidence risks for a 30 years man: 1.94 ± 0.22% Vs. 1.68 ± 0.17%; and women: 6.66 ± 0.81% Vs. 4.60 ± 0.43%: cancer mortality risks for 30 years men: 1.63 ± 0.19% Vs. 1.45 ± 0.15%; and women: 3.63 ± 0.44% Vs. 2.94 ± 0.23%). CONCLUSION: All the radiotherapy techniques had low cancer risks. However, the overall estimated risks induced by IMRT and VMAT radiotherapy techniques were lower than the 3D-CRT techniques and can be used clinically in younger patients or patients having greater concerns about radiation induced cancers.
引用
- Banaei A, Hashemi B, Bakhshandeh M, et al. Estimating cancer risks due to whole lungs low dose radiotherapy with different techniques for treating COVID-19 pneumonia. Radiat Oncol. 2022. PMID: 35057839. doi:10.1186/s13014-021-01971-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。